- September 2014
Discussing how healthcare systems can meet the needs of cancer survivors.
- July/August 2014
Sophie Postel-Vinay on new recommendations for phase 1 trials.
- June 2014
Hans Clevers on important research into stem cells in normal gut tissue.
- May 2014
Carolyn Taylor and Paul McGale find evidence to clarify guidelines for radiotherapy after mastectomy.
- April 2014
Richard Sullivan and Ajay Aggarwal on how physicians can tackle the issue of affordability in cancer care.
- March 2014
The 1st EORTC Cancer Survivorship Summit addressed the practical problems faced by cancer patients.
- February 2014
Charles Swanton on a study that maps genetic changes in cancers over time.
- January 2014
Presidents of various cancer societies make predictions for the coming year.
- December 2013
Precision diagnostics have great potential, but changes are needed to make them more available.
- November 2013
Highlights of the European Cancer Congress - cancer society presidents give their view.
- October 2013
Richard Schilsky on the changes needed as personalised medicine enters the clinic.
- September 2013
A new advance in immunotherapy is discussed by Jean-Charles Soria and Caroline Robert.
EJC News Focus – September 2013
EJC's Drug of the Year, 2013
Immunotherapy is finally emerged from the shadows as a realistic – and perhaps essential – tool in cancer control. After decades of painstaking research which yielded little benefit for patients, immunotherapy has entered a fresh phase with the development of new agents that can either activate the immune system or re-awaken silenced immune responses to a tumour.
The emerging paradigm, by which only the most effective immune cells are selectively harnessed to target the tumour, is an immediate advance for patients. It also holds the promise of future steps forward, as clinicians and researchers learn how best to use the new agents in combination.
In this month's EJC News Focus, Jean-Charles Soria and Caroline Robert, both from Institut Gustave Roussy, Paris-Sud, France, explain to Helen Saul why the Programmed Death-1 receptor (PD-1), and its ligand (PD-L1), have been recognised in EJC's Drug of the Year article, 2013.